|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Squamous Cell Carcinoma and Adenocarcinoma of the Esophagus–Di?erences in Etiology, Epidemiology and Prevention显示文摘In Germany, esophageal carcinoma is one of the ten most frequent causes of death. Normally the disease is found in men over the age of 50. Although squamous cell carcinoma (SCC) of the esophagus has been more commonly diagnosed over the past 30 years, there is increasing incidence of esophageal adenocarcinoma (AC) in Western industrialized countries. For SCC the known etiological risk factors are nicotine and alcohol abuse. For AC, they are moderate nicotine and alcohol consumption as well as gastro-esophageal re?ux and obesity. | Elfriede Bollschweiler Eva Wolfgarten | 2004 | The Chinese-German Journal of Clinical Oncology2004，3，4： | 8 |
| 2 | Treatment of early gastric cancer in the Western World显示文摘The incidence rate of gastric cancer is much higher in Asia than in the Western industrial nations.According to the different screening programs in Japan and Korea about fifty percent of treated patients had an early tumor stage.In contrast,European and American patients with gastric cancer had an advanced tumor stage.Therefore,the experience for the various therapeutic options for gastric cancer may be different between these regions.In this review we tried to point out the treatment modalities in Western industrial countries for early gastric cancer. | Elfriede Bollschweiler Felix Berlth Christoph Baltin Stefan Mnig Arnulf H Hlscher | 2014 | World Journal of Gastroenterology2014，20，19： | 8 |
| 3 | Pathohistological classification systems in gastric cancer:Diagnostic relevance and prognostic value显示文摘Several pathohistological classification systems exist for the diagnosis of gastric cancer.Many studies have investigated the correlation between the pathohistological characteristics in gastric cancer and patient characteristics,disease specific criteria and overall outcome.It is still controversial as to which classification system imparts the most reliable information,and therefore,the choice of system may vary in clinical routine.In addition to the most common classification systems,such as the Laurén and the World Health Organization(WHO)classifications,other authors have tried to characterize and classify gastric cancer based on the microscopic morphology and in reference to the clinical outcome of the patients.In more than 50 years of systematic classification of the pathohistological characteristics of gastric cancer,there is no sole classification system that is consistently used worldwide in diagnostics and research.However,several national guidelines for the treatment of gastric cancer refer to the Laurén or the WHO classifications regarding therapeutic decision-making,which underlines the importance of a reliable classification system for gastric cancer.The latest results from gastric cancer studies indicate that it might be useful to integrate DNA-and RNA-based features of gastric cancer into the classification systems to establish prognostic relevance.This article reviews the diagnostic relevance and the prognostic value of different pathohistological classification systems in gastric cancer. | Felix Berlth Elfriede Bollschweiler Uta Drebber Arnulf H Hoelscher Stefan Moenig | 2014 | World Journal of Gastroenterology2014，20，19： | 6 |
| 4 | Cytochrome P450 levels are altered in patients with esophageal squamous-cell carcinoma显示文摘AIM: To investigate the role of cytochrome P450 (CYP) in the carcinogenesis of squamous-cell carcinoma (SCC) in human esophagus by determining expression patterns and protein levels of representative CYPs in esophageal tissue of patients with SCC and controls. METHODS: mRNA expression of CYP2E1, CYP2C, CYP3A4, and CYP3A5 was determined using RT-PCR in both normal and malignant esophageal tissues of patients with untreated esophageal SCC (n = 21) and in controls (n = 10). Protein levels of CYP2E1, CYP2C8, CYP3A4, and CYP3A5 were measured by Western blot. RESULTS: Within the group of SCC patients, mRNA expression of CYP 3A4 and CYP2C was significantly lower in malignant tissue (-39% and -74%, respectively, P < 0.05) than in normal tissue. Similar results were found in CYP3A4 protein levels. Between groups, CYP3A4, CYP3A5, and CYP2C8 protein concentration was significantly higher in non-malignant tissue of SCC patients (4.8-, 2.9-, and 1.9-fold elevation, P < 0.05) than in controls. In contrast, CYP2E1 protein levels were significantly higher in controls than in SCC patients (+46%, P < 0.05). CONCLUSION: Significant differences exist in protein levels of certain CYPs in non-malignant esophageal tissue (e.g. CYP2C8, CYP3A4, CYP3A5, and CYP2E1) between SCC patients and healthy subjects and may contribute to the development of SCC in the esophagus. | I Bergheim E Wolfgarten E Bollschweiler AH Hlscher C Bode A Parlesak | 2007 | World Journal of Gastroenterology2007，13，7： | 6 |
| 5 | Neoadjuvant treatment for advanced esophageal cancer: response assessment before surgery and how to predict response to chemoradiation before starting treatment显示文摘Patients with advanced esophageal cancer(T3-4, N) have a poor prognosis. Chemoradiation or chemotherapy before esophagectomy with adequate lymphadenectomy is the standard treatment for patients with resectable advanced esophageal carcinoma. However, only patients with major histopathologic response(regression to less than 10% of the primary tumor) after preoperative treatment will have a prognostic benefit of preoperative chemoradiation. Using current therapy regimens about 40% to 50% of the patients show major histopathological response. The remaining cohort does not benefit from this neoadjuvant approach but might benefit from earlier surgical resection. Therefore, it is an aim to develop tools for response prediction before starting the treatment and for early response assessment identifying responders. The current review discusses the different imaging techniques and the most recent studies about molecular markers for early response prediction. The results show that [18F]-fluorodeoxyglucose-positron emission tomography(FDGPET) has a good sensitivity but the specificity is not robust enough for routine clinical use. Newer positron emission tomography detector technology, the combination of FDG-PET with computed tomography, additional evaluation criteria and standardization of evaluation may improve the predictive value. There exist a great number of retrospective studies using molecular markers for prediction of response. Until now the clinical use is missing. But the results of first prospective studies are promising. A future perspective may be the combination of imaging technics and special molecular markers for individualized therapy. Another aspect is the response assessment after finishing neoadjuvant treatment protocol. The different clinical methods are discussed. The results show that until now no non-invasive method is valid enough to assess complete histopathological response. | Elfriede Bollschweiler Arnulf H.Hlscher Matthias Schmidt Ute Warnecke-Eberz | 2015 | Chinese Journal of Cancer Research2015，27，3： | 3 |
| 6 | Association of the GNAS1 T393C polymorphism with tumor stage and survival in gastric cancer显示文摘AIM:To analyze the impact of the GNAS1 T393C polymorphism on prognosis and histopathology of gastric cancer.METHODS:Genomic DNA was extracted from paraffinembedded tissues of 122 patients with primary gastric carcinoma and from the blood of 820 healthy white individuals.Allelic discrimination was performed by quantitative real-time polymerase chain reaction.Genotyping was correlated with histopathologic parameters and with overall survival according to the Kaplan-Meier approach and with multivariate analysis by multiple stepwise regression.RESULTS:Thirty-nine(32%) patients displayed a CC genotype,57(46.7%) a CT genotype and 26(21.3%) a TT genotype.The frequency of the C allele(fC) in the patient group was 0.55,which was not signif icantly different from that of healthy blood donors.The distribution was compatible with the Hardy-Weinberg equilibrium.Analysis of clinicopathological parameters did not show any signif icant correlation of the T393C genotype with gender(P=0.50),differentiation(P=0.29),pT-category(P=0.19),pN-category(P=0.30),pM-category(P=0.25),R-category(P=0.95),the classifications according to WHO(P=0.34),Laurén(P=0.16),Goseki(P=1.00) and Ming(P=0.74).Dichotomization between C+(CC+CT) and C-genotypes(TT),however,revealed signif icantly more advanced tumor stages(P=0.023) and lower survival rates(P=0.043) for C allele carriers.CONCLUSION:The present study provides strong evidence to suggest that the GNAS1 T393C allele carrier status influences tumor progression and survival in gastric cancer with higher tumor stages and a worse outcome for C allele carriers. | Hakan Alakus Stefan P Mnig Ute Warnecke-Eberz Gül Alakus Günther Winde Uta Drebber Klaus J Schmitz Kurt W Schmid Kathrin Riemann Winfried Siffert Elfriede Bollschweiler Arnulf H Hlscher Ralf Metzger | 2009 | World Journal of Gastroenterology2009，15，48： | 3 |
| 7 | Histomorphologic Tumor Regression and Lymph Node Metastases Determine Prognosis Following Neoadjuvant Radiochemotherapy for Esophageal Cancer: Implications for Response Classification显示文摘 | Paul M. Schneider Stephan E. Baldus Ralf Metzger Martin Kocher Rudolf Bongartz Elfriede Bollschweiler Hartmut Schaefer Juergen Thiele Hans P. Dienes Rolf P. Mueller Arnulf H. Hoelscher | 2005 | Annals of Surgery2005，，5： | 2 |
| 8 | Altered levels of the onco-microRNA 21 and the tumor-supressor microRNAs143 and 145 in advanced rectal cancer indicate successful neoadjuvant chemoradiotherapy显示文摘 | Uta Drebber Max Lay Inga Wedemeyer Daniel Vallb?hmer Elfriede Bollschweiler Jan Brabender Stefan M?nig Arnulf H?lscher Hans Dienes Margarete Odenthal | 2011 | International Journal of Oncology2011，，： | 2 |
| 9 | 食管黏膜下鳞状细胞癌及腺癌的高淋巴结转移率显示文摘Background and study aims: The application of endoscopic mucosectomy in early esophageal cancer is limited by the presence of lymph-node metastasis. The aim of this prospective study was to analyze the rate of lymph-node involvement relative to the depth of mucosal or submucosal tumor penetration, comparing squamous-cell carcinomas and adenocarcinomas. Patients and methods: A total of 60 patients with pT1 esophageal cancer- 24 with squamous-cell carcinomas (SCCs) and 36 with adenocarcinomas- were treated with transthoracic enbloc esophagectomy with two-field lymphadenectomy (n = 50) or transhiatal esophageal resection (n = 10). An average of 30 lymph nodes were examined, and the following characteristics were evaluated: histology, mucosal infiltration, depth of submucosal wall infiltration in three thirds (sm1, sm2, sm3), grading, resection category, ratio of metastatic to resected lymph nodes, and locations of metastatic nodes. Results: The rates of lymph-node metastasis were 0% for the 16 mucosal carcinomas and 45% for the 44 submucosal carcinomas (P< 0.01). There were no significant differences in the extent of lymph-node involvement between submucosal adenocarcinomas (41% ) and submucosal SCCs (50% ). Sm1 carcinomas were associated with a lower rate of lymph-node metastasis (SCCs 33% , adenocarcinomas 22% ) than sm3 carcinomas (SCCs 69% , adenocarcinomas 78% ). Two patients (9% ) with submucosal SCCs and five patients (23% ) with submucosal adenocarcinomas were classified as having stage pM1 lymph. The average lymph-node ratio in patients with pN1 was 0.13 for adenocarcinomas and 0.1 for SCCs (difference not significant). In the multivariate analysis, the parameters mucosal vs. submucosal (P < 0.01) and G1/G2 vs. G3 (P < 0.05) showed a significant impact in relation to metastatic lymph nodes. Conclusions: The most important factor for predicting lymph-node metastasis in early esophageal cancer is the presence of submucosal infiltration. Early adenocarcinomas and SCCs do not differ with regard to their rate of lymphatic involvement. The rate of lymph-node metastasis increases with the depth of submucosal infiltration, but metastases can already occur in sm1 lesions. Submucosal infiltration is a contraindication for endoscopic mucosectomy. Limited surgical procedures without adequate lymphadenectomy do not appear to be appropriate in the treatment of patients with submucosal esophageal carcinomas. | Bollschweiler E. Baldus S.E. Schrder W. A.H. Hlscher 张红凯 | 2006 | 世界核心医学期刊文摘(胃肠病学分册)2006，2，8： | 2 |
| 10 | Prognostic relevance of skip metastases in esophageal cancer显示文摘 | Prenzel KL Bollschweiler E Schr(o)der W | 2010 | Ann Thorac Surg2010，90，： | 1 |
| 11 | Comparison between endoscopic and surgical resection of mucosal esophageal adenocarcinoma in Barrett's esophagus at two high-volume centers显示文摘 | PECH O BOLLSCHWEILER E MANNER H | 2011 | Ann Surg2011，254，1： | 1 |
| 12 | Demographic var- iations in the rising incidence of esophageal adenocarcinoma in white males显示文摘 | Bollschweiler E Wolfgarten E Gutschow C | 2001 | Cancer2001，92，3： | 1 |
| 13 | A Multicenter Study of Survival After Neoadjuvant Radiotherapy/Chemotherapy and Esophagectomy for ypT0N0M0R0 Esophageal Cancer显示文摘 | D. Vallb?hmer Arnulf H. H?lscher S. DeMeester T. DeMeester J. Salo J. Peters T. Lerut S. G. Swisher W. Schr?der E. Bollschweiler W. Hofstetter | 2010 | Annals of Surgery2010，，5： | 1 |
| 14 | Prognostic relevance of skip metastases in esophageal cancer显示文摘 | Prenzel KL Bollschweiler E Schrtider W | 2010 | Ann Thorac Surg2010，90，5： | 1 |
| 15 | Korreliert der Charlson-Comorbidity-Index mit dem postoperativen Verlauf bei Patienten mit Magenkarzinom?显示文摘 | T. Lübke S. M?nig P. Schneider A. H?lscher E. Bollschweiler | 2003 | Zentralbl Chir2003，，11： | 1 |
| 16 | Histolog-ic tumor type and the rate of complete response after neoadjuvanttherapy for esophageal cancer 显示文摘 | BOLLSCHWEILER E HoLSCHER A H METZGER R | 2010 | Future Oncol2010，6，1： | 1 |
| 17 | Prognostic relevance of skip metastases in esophageal cancer显示文摘 | Prenzel KL Bollschweiler E Schroder W | 2010 | Ann Thorac Surg2010，90，5： | 1 |
| 18 | Preoperative risk analysis in patients with adenocarcinoma or squamous cell carcinoma of the oesophagus显示文摘 | Bollschweiler E Schroder W Holscher AH et al | 2000 | Br J Surg2000，87，8： | 1 |
| 19 | Evaluation of POSSUM scoring system in patients with gastric cancer undergoing D2-gastrectomy显示文摘 | Bollschweiler E Lubke T Monig Sp | 2005 | BMC Surg2005，5，1： | 1 |
| 20 | Evaluation of POSSUM scoring system in patients with gastric cancer undergoing D2-gastrectomy显示文摘 | Bollschweiler E Lubke T Monig SP | 2005 | BMC Surg2005，15，5： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员